Third-generation EGFR tyrosine kinase inhibitors (TKIs) designed to overcome the T790M mutation have been shown to double progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations, according to reports at the European Lung Cancer Conference (ELCC) 2016 held recently in Geneva, Switzerland.
LUX-Lung 7, a global phase IIb, randomized, open-label trial, demonstrated significant improvements in progression-free survival (PFS), time to treatment failure (TTF) and objective response rate (ORR) with afatinib vs gefitinib as first-line treatment for patients with advanced, EGFR-positive non-small-cell lung cancer (NSCLC). [ELCC 2016, abstract 140PD]
A combination of live-bacterium immunotherapy and standard chemotherapy is safe and effective in patients with malignant pleural mesothelioma (MPM), providing a response rate of nearly 60 percent, according to a recent phase Ib trial. [ELCC 2016, abstract 208O_PR]
Several new studies presented at the European
Lung Cancer Conference (ELCC) 2016 have confirmed the benefit of plasma circulating tumour DNA (ctDNA) testing for EGFR mutation analysis to predict treatment benefit of targeted therapies for non-small-cell lung cancer (NSCLC). Tissue biopsy, the gold standard for tumour genotyping, is not feasible in about 20 percent of patients, and plasma biomarkers are a potential alternative.
The development of immunotherapy and recent approval of agents which block various components of the immune checkpoint pathway, such as programmed cell death-1 (PD-1) receptor and its ligand PD-L1, have revolutionized lung cancer treatment.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Pharmacy - Malaysia digital copy today!
Pearl Toh spoke with Dr Teh Ming Ming, senior consultant at the Department of Endocrinology, Singapore General Hospital (SGH), on the major challenges of diagnosing and managing diabetes in primary care, in conjunction with the World Diabetes Day on 14 November. Awareness of the symptoms of diabetes is important, and patients should be empowered to manage their conditions.
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.